US Patent 7,148,359: Amorphous Ritonavir Claims, Expiration, and Patent Landscape

US Patent 7,148,359 protects amorphous ritonavir as a solid-state form and protects compositions in which ritonavir is present in amorphous form. The patent does not claim ritonavir as a chemical compound, a specific dosage strength, a tablet, capsule, oral solution, or a manufacturing process. Its commercial relevance was tied to the physical form of ritonavir used in products such as Norvir and ritonavir-containing combination therapies.

The patent issued on December 12, 2006, to Abbott Laboratories. Its nominal patent term ended in 2020 based on the earliest claimed priority date. The patent therefore does not present a current US exclusivity barrier to generic ritonavir development. Its principal value today is historical: it illustrates the solid-state and formulation strategies used to protect ritonavir after the basic compound patents expired.

What does US Patent 7,148,359 claim?

The patent contains seven claims directed to two related categories:

Substantially pure amorphous ritonavir as a material.
Compositions containing amorphous ritonavir.

Claim	Claim type	Principal limitation
1	Independent product claim	Substantially pure amorphous ritonavir
2	Dependent product claim	Claim 1, with glass transition temperature of about 45°C to about 49°C
3	Independent composition claim	A composition comprising amorphous ritonavir
4	Dependent composition claim	The amorphous ritonavir is substantially pure
5	Dependent composition claim	More than about 90% of ritonavir is amorphous
6	Dependent composition claim	More than about 95% of ritonavir is amorphous
7	Dependent composition claim	More than about 97% of ritonavir is amorphous

Claims 1 and 3 are the principal scope provisions. Claims 2 and 4-7 narrow those claims through physical-characterization or concentration requirements. (U.S. Patent No. 7,148,359, 2006)

What is the technical scope of the amorphous ritonavir claims?

Claim 1: substantially pure amorphous ritonavir

Claim 1 covers the material itself rather than a particular product containing it. A product would potentially fall within the claim if the ritonavir active ingredient is:

Ritonavir in an amorphous solid-state form; and
"Substantially pure" under the claim construction applied to the patent.

The claim does not specify a particle size, dosage, excipient, route of administration, manufacturing process, solvent system, or particular analytical method.

The most important claim-construction issues are the meanings of "amorphous" and "substantially pure." Amorphous ritonavir lacks the long-range molecular order associated with a crystalline polymorph. A material can contain both amorphous and crystalline ritonavir, raising the question of whether the amount of crystalline material is sufficient to remove the material from claim 1.

"Substantially pure" may refer to chemical purity, solid-state purity, or both. The specification and prosecution history would control the interpretation. The phrase creates a potential litigation issue because it does not state a fixed impurity threshold in the claim itself.

Claim 2: glass transition temperature

Claim 2 narrows claim 1 to amorphous ritonavir characterized by a glass transition temperature of approximately 45°C to 49°C.

This limitation is analytically significant because the measured glass transition temperature can depend on:

Water content;
Residual solvent;
Heating rate;
Differential scanning calorimetry conditions;
Sample history;
Degree of crystallinity; and
Instrument calibration.

The "about" language gives the claim some tolerance around the stated temperature range. It does not eliminate the need to establish the test method and relevant measurement conditions.

A generic manufacturer could avoid claim 2 if its amorphous ritonavir has a glass transition outside the claimed range. That would not necessarily avoid claim 1 or the composition claims.

How broad are the composition claims?

Claim 3: any composition comprising amorphous ritonavir

Claim 3 is broad on its face. It covers a composition containing amorphous ritonavir without specifying:

The amount of amorphous ritonavir;
The identity or quantity of excipients;
The dosage form;
The therapeutic indication;
The route of administration;
The glass transition temperature; or
The percentage of ritonavir that is amorphous.

The claim could potentially reach a pharmaceutical formulation containing a mixture of amorphous and crystalline ritonavir, provided the composition contains amorphous ritonavir. The exact scope would depend on construction of "comprising" and on whether the composition must be pharmaceutical or may include an intermediate, bulk material, or analytical sample.

Claims 4-7: purity and amorphous-content thresholds

Claims 4-7 add progressively narrower limitations.

Claim 4 requires substantially pure amorphous ritonavir. Claims 5-7 focus on the percentage of total ritonavir in the composition that is amorphous.

The claims are nested in practical terms:

A composition containing 98% amorphous ritonavir would satisfy the greater-than-90% and greater-than-95% limitations, assuming all other claim elements are met.
A composition containing 96% amorphous ritonavir would satisfy the greater-than-90% and greater-than-95% limitations but not the greater-than-97% limitation.
A composition containing 92% amorphous ritonavir would satisfy the greater-than-90% limitation but not the higher thresholds.
A composition containing exactly 90%, 95%, or 97% would not literally satisfy a "greater than" limitation, although the meaning of "about" may affect the analysis.

Amorphous ritonavir content	Claim 5	Claim 6	Claim 7
90%	Potentially no	No	No
92%	Yes	No	No
95%	Yes	Potentially no	No
96%	Yes	Yes	No
97%	Yes	Yes	Potentially no
98%	Yes	Yes	Yes

The claims do not define the analytical method for determining the percentage of amorphous ritonavir. That issue can be material because powder X-ray diffraction, solid-state NMR, thermal analysis, and other methods may produce different sensitivity levels for low amounts of crystalline material.

When did US Patent 7,148,359 expire?

The patent’s nominal US term expired in 2020, calculated from the earliest claimed priority date. The patent issued on December 12, 2006, but the issue date does not determine the end of the standard patent term for a post-1995 US application.

Event	Date or status
Earliest claimed priority	1999
US patent issued	December 12, 2006
Patent number	US 7,148,359
Nominal statutory expiration	2020
Current enforcement status	Expired by term
Patent term extension	No relevant extension identified for this solid-state patent

The patent’s expiration means that a US manufacturer is no longer required to obtain a license to practice the claimed amorphous ritonavir subject matter. The expiration also removes the patent as a basis for a current injunction against a generic product.

Patent expiration does not eliminate possible exposure under other ritonavir patents, trade secrets, regulatory exclusivities, contractual restrictions, or patents covering a particular formulation or manufacturing process.

What was the FDA and Orange Book relevance of the patent?

Ritonavir was approved by the FDA as Norvir under NDA 20-945. The product has been used both as a standalone HIV protease inhibitor and as a pharmacokinetic booster for other protease inhibitors and antiviral regimens. The FDA-approved product forms have included capsules, tablets, and oral solution formulations. (U.S. Food and Drug Administration, n.d.-a)

US 7,148,359 is a solid-state patent. It does not claim the ritonavir molecule itself or a complete approved dosage form. Its potential Orange Book relevance would therefore have depended on whether Abbott listed it against an approved product and whether the listed claims covered the approved formulation.

The Orange Book distinguishes between patents claiming the active ingredient, drug product, formulation, method of use, or other listed subject matter. A patent covering amorphous active ingredient material may be relevant to a product containing that form, but it does not automatically cover every ritonavir product. (U.S. Food and Drug Administration, n.d.-b)

Because US 7,148,359 has expired, it is not a current Orange Book barrier to ANDA approval or generic launch. Any present Paragraph IV strategy would need to address unexpired patents listed for the relevant ritonavir reference product, not this expired patent.

What Paragraph IV challenges and litigation affected US 7,148,359?

A Paragraph IV certification is relevant when an ANDA applicant asserts that a listed patent is invalid, unenforceable, or not infringed. The commercial consequence can include a 30-month FDA approval stay if the patent owner brings a timely infringement action. (21 U.S.C. § 355(j))

No major reported US Paragraph IV litigation directed specifically to US 7,148,359 is identified in the patent record and cited regulatory materials. The patent’s commercial threat was more significant before its 2020 expiration, when an ANDA applicant could have faced infringement allegations based on the amorphous form or amorphous content of its active ingredient.

The principal litigation theories would have included:

Whether the generic contained amorphous rather than crystalline ritonavir;
Whether the amorphous material was "substantially pure";
Whether the composition contained more than 90%, 95%, or 97% amorphous ritonavir;
Whether the generic’s material had a glass transition temperature within the claim 2 range;
Whether the claimed form was anticipated by earlier ritonavir solid-state disclosures; and
Whether the claims were obvious in view of known amorphization techniques and ritonavir’s known instability or formulation problems.

Because the patent has expired, these issues now have limited prospective litigation value except in damages, historical validity, or contractual disputes.

How strong was the patent estate for amorphous ritonavir?

The estate was commercially meaningful but structurally narrow compared with a basic compound patent.

Strengths

The patent had several features favorable to enforcement during its term:

Claim 1 targeted the active pharmaceutical ingredient in a defined solid-state form.
Claim 3 was broad because it covered a composition comprising amorphous ritonavir.
The dependent claims supplied fallback positions based on purity and amorphous content.
Claim 2 added a measurable physical characteristic that could support product testing.
The claims did not depend on a particular brand, dosage strength, or excipient combination.

Weaknesses

The estate also had limitations:

It did not cover crystalline ritonavir.
It did not cover ritonavir generally.
It did not claim a specific tablet, capsule, or oral-solution formulation.
The terms "substantially pure," "amorphous," and "about" could create claim-construction disputes.
The percentage claims require a reliable method for quantifying amorphous content.
An alternative crystalline form or a formulation using a different solid-state profile could avoid literal infringement.
The patent was vulnerable to obviousness arguments based on routine solid-state screening and known pharmaceutical techniques.

The patent’s strongest practical position was against a generic that intentionally reproduced the same amorphous ritonavir material used in the reference product. Its weakest position was against a manufacturer using a crystalline form, a different solid-state composition, or a formulation in which amorphous content fell outside the claimed thresholds.

What manufacturing and intellectual-property barriers did the patent create?

The patent could affect generic development at three stages:

Active pharmaceutical ingredient selection

A generic developer would need to determine whether its ritonavir API was amorphous, crystalline, or a mixture. Routine manufacturing conditions such as solvent evaporation, drying, milling, temperature exposure, and storage could alter the solid state.

Formulation development

Amorphous ritonavir may have different dissolution, stability, hygroscopicity, and bioavailability characteristics from crystalline material. A developer could therefore face formulation constraints even if it avoided the patent by selecting a different polymorph.

Quality-control testing

A generic applicant would need solid-state controls capable of distinguishing the relevant form and quantifying amorphous content. This is important because a material initially manufactured as crystalline ritonavir could partially amorphize during processing or storage.

The patent itself was not a manufacturing-process patent. It did not prevent all production of ritonavir. It potentially restricted the commercial use of a specified physical form and compositions containing that form during the patent term.

How does US 7,148,359 compare with other ritonavir patent categories?

Patent category	Subject matter	Effect after 2020
Basic compound patents	Ritonavir molecule and related protease inhibitors	Generally expired before or around the period relevant to generic entry
Solid-state patents	Amorphous or crystalline ritonavir forms	US 7,148,359 expired in 2020
Formulation patents	Tablets, capsules, solutions, dispersions, excipient systems	Must be reviewed separately; expiration dates vary
Method-of-use patents	HIV treatment, boosting, or combination therapy	May have separate terms and claim limitations
Manufacturing patents	Synthesis, purification, crystallization, or drying	May create process-specific exposure
Regulatory exclusivity	FDA exclusivity associated with an approved product	Separate from patent term and generally limited in duration

Ritonavir is a small molecule, so biosimilar risk does not apply. Generic competition proceeds through the ANDA pathway rather than the biosimilar pathway under the Public Health Service Act. The relevant competitive threats are generic ritonavir products and combination products using ritonavir as a booster.

Which companies are challenging or competing with ritonavir products?

The competitive field includes:

Generic manufacturers selling ritonavir tablets, capsules, or oral solution;
Developers of combination HIV therapies that include ritonavir;
Manufacturers using ritonavir as a pharmacokinetic booster;
Developers using alternative boosters, particularly cobicistat, in products where the clinical and regulatory profile permits substitution.

The main commercial distinction is between standalone ritonavir and ritonavir used as a booster. Standalone Norvir has a narrower market role than combination products such as lopinavir/ritonavir and other regimens in which ritonavir is included primarily to increase exposure to another active ingredient.

No license is required to practice US 7,148,359 after expiration. The patent record does not establish a continuing license obligation for generic manufacturers. Commercial agreements involving HIV products, distribution, or combination therapies are separate from the expired patent rights.

What generic launch scenarios existed under the patent?

Before expiration, the main launch scenarios were:

Scenario	Patent position	Commercial result
Generic uses the same substantially pure amorphous form	High potential exposure to claims 1 and 3	Paragraph IV or delayed launch likely required
Generic uses 98% amorphous ritonavir	Potential exposure to claims 1, 3, 5, 6, and 7	Strongest overlap
Generic uses 92% amorphous ritonavir	Potential exposure to claims 1, 3, and 5	Narrower but still material overlap
Generic uses predominantly crystalline ritonavir	Reduced risk under claims directed to amorphous material	Requires separate product-performance assessment
Generic uses a mixed form below claimed thresholds	Possible avoidance of claims 5-7	Claims 1 and 3 remain relevant during term
Product launches after 2020	Patent term expired	No infringement risk from this patent

Today, the patent does not delay a US generic launch. The relevant analysis shifts to active Orange Book patents, FDA requirements, bioequivalence, product-specific formulation patents, and manufacturing controls.

Key Takeaways

US 7,148,359 claims amorphous ritonavir, not ritonavir generally.
Claim 1 is directed to substantially pure amorphous ritonavir as a material.
Claim 2 adds a glass transition range of about 45°C to about 49°C.
Claim 3 broadly covers compositions comprising amorphous ritonavir.
Claims 5-7 create nested thresholds at greater than about 90%, 95%, and 97% amorphous ritonavir.
The principal legal issues would have involved the meanings of "substantially pure," "amorphous," "about," and the method used to quantify amorphous content.
The patent expired in 2020 and is not a current US generic-entry barrier.
Ritonavir is a small molecule, so biosimilar litigation is not relevant.
Current freedom-to-operate analysis must focus on any unexpired formulation, method-of-use, manufacturing, or combination-product patents.

FAQs About US Patent 7,148,359 and Amorphous Ritonavir

Does US Patent 7,148,359 cover crystalline ritonavir?

No. The claims require amorphous ritonavir. A crystalline ritonavir product would not literally satisfy that central limitation, although a mixed composition could require analysis under the composition claims.

Does the patent cover Norvir tablets?

Potentially during the patent term, if the tablets contained amorphous ritonavir and met the relevant claim limitations. The patent did not claim Norvir tablets by brand name or by a complete tablet formulation.

Can a generic use amorphous ritonavir after the patent expired?

Yes. Expiration ended the patent owner’s right to prevent practice of the claimed amorphous ritonavir subject matter in the United States.

Is claim 3 broader than claim 1?

Yes. Claim 3 covers a composition comprising amorphous ritonavir and does not expressly require the amorphous ritonavir to be substantially pure. Claim 1 claims the material itself and requires substantial purity.

Are there biosimilar versions of ritonavir?

No. Ritonavir is a small-molecule drug regulated through the generic drug pathway. Manufacturers submit ANDAs rather than biosimilar applications.

References

Abbott Laboratories. (2006). Amorphous form of ritonavir, U.S. Patent No. 7,148,359. United States Patent and Trademark Office.
Food and Drug Administration. (n.d.-a). Norvir (ritonavir) prescribing information and approval history. U.S. Department of Health and Human Services.
Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
U.S. Code. (2024). 21 U.S.C. § 355(j): Abbreviated applications for new drugs. Office of the Law Revision Counsel.
U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent term calculation resources. United States Department of Commerce.

Details for Patent: 7,148,359

Summary for Patent: 7,148,359